Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares, a decrease of 33.6% from the February 13th total of 11,000 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 14,300 shares, the short-interest ratio is presently 0.5 days.
Hedge Funds Weigh In On Lakeshore Biopharma
Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC purchased a new stake in Lakeshore Biopharma in the third quarter valued at approximately $803,000. Hhlr Advisors LTD. purchased a new stake in Lakeshore Biopharma in the third quarter valued at approximately $513,000. Barclays PLC purchased a new stake in Lakeshore Biopharma in the third quarter valued at approximately $169,000. Finally, Orbimed Advisors LLC purchased a new stake in Lakeshore Biopharma in the fourth quarter valued at approximately $486,000. 52.64% of the stock is currently owned by hedge funds and other institutional investors.
Lakeshore Biopharma Stock Performance
Shares of LSB stock traded up $0.14 during mid-day trading on Friday, hitting $2.04. The stock had a trading volume of 6,868 shares, compared to its average volume of 20,002. Lakeshore Biopharma has a fifty-two week low of $1.81 and a fifty-two week high of $11.20. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.13. The company’s 50-day simple moving average is $2.45 and its 200-day simple moving average is $3.39.
Lakeshore Biopharma Company Profile
LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.
Featured Articles
- Five stocks we like better than Lakeshore Biopharma
- With Risk Tolerance, One Size Does Not Fit All
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- The Most Important Warren Buffett Stock for Investors: His Own
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Golden Cross Stocks: Pattern, Examples and Charts
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Lakeshore Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakeshore Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
